ZIVO Zivo Bioscience, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1101026 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY164.5%
TTM net income YoY38.0%
TTM EPS YoY45.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin31.7%
Operating margin-4,045.7%
Net margin-4,059.7%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,608.6%
ROIC (approx.)—
Asset turnover0.40x
Leverage & solvency
Liabilities / assets687.5%
Debt / equity—
Current ratio0.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-1,025.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $157,220 | $27,650 | $0 | $0 | $20,000 |
| Cost of revenue | $108,268 | $16,040 | $0 | — | — |
| Gross profit | $48,952 | $11,610 | $0 | — | — |
| R&D expense | $3.13M | $1.38M | $2.24M | $1.95M | $3.75M |
| SG&A expense | $10.28M | $5.90M | $6.49M | $6.69M | $4.82M |
| Operating income | -$13.36M | -$7.26M | -$8.73M | -$8.65M | -$8.56M |
| Interest expense | — | $23,793 | $13,319 | $44,677 | $97,630 |
| Net income | -$13.38M | -$7.78M | -$8.75M | -$8.76M | -$9.11M |
| EBITDA | — | — | — | -$8.65M | -$8.56M |
| EPS (basic) | — | — | — | — | -0.02 |
| EPS (diluted) | -4.23 | -4.60 | — | — | -0.02 |
| Dividends declared per share | — | 3.11 | — | — | — |
| Weighted avg. shares (diluted) | 3.17M | 1.69M | — | — | 406.18M |
| Balance sheet | |||||
| Cash & equivalents | $1.54M | $274,380 | $1.80M | $8.90M | $137,862 |
| Current assets | $1.64M | $425,377 | $1.90M | $8.96M | $167,815 |
| PP&E, net | — | $0 | $0 | $0 | $0 |
| Total assets | $1.64M | $555,715 | $2.12M | $8.99M | $220,179 |
| Current liabilities | $2.04M | $2.76M | $2.03M | $2.95M | $11.39M |
| Short-term debt | $0 | $0 | $105,919 | $0 | — |
| Total liabilities | $2.16M | $2.76M | $2.13M | $2.95M | $11.53M |
| Shareholders' equity | -$514,898 | -$2.21M | -$10,622 | $6.04M | -$11.31M |
| Shares outstanding | 3.62M | 2.38M | 1.57M | 9.42M | 5.16M |
| Cash flow statement | |||||
| Operating cash flow | -$4.31M | -$5.80M | -$7.10M | -$6.80M | -$2.59M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $5.58M | $4.28M | $0 | $15.57M | $2.38M |
| Depreciation & amortization | — | — | — | $0 | $0 |
| Stock-based compensation | $1.51M | $89,502 | -$297,653 | -$104,601 | $1.25M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.